viral
infect
common
caus
viral
infect
common
caus
upper
lower
respiratori
tract
infect
frequent
reason
outpati
offic
visit
compar
viral
respiratori
infect
less
common
intens
care
unit
icu
set
still
play
import
clinic
role
viral
respiratori
infect
icu
communityassoci
case
sever
lower
respiratori
diseas
progress
respiratori
failur
acut
respiratori
distress
syndrom
ard
remaind
infect
seen
immunocompromis
patient
transplant
instanc
sever
acut
respiratori
syndrom
sar
influenza
adenoviru
viral
respiratori
infect
present
fulmin
respiratori
failur
ard
herald
larger
commun
outbreak
situat
newli
recogn
ill
icu
patient
might
first
present
larger
public
health
emerg
clinic
present
treatment
outcom
person
institut
infect
control
differ
greatli
among
common
viral
infect
icu
differ
larg
base
viral
structur
mode
transmiss
cell
entri
host
immunolog
thu
provid
foundat
clinic
present
virul
medic
therapeut
viral
infect
therefor
basic
knowledg
common
icu
viral
respiratori
pathogen
provid
framework
clinic
research
approach
infect
review
focu
basic
epidemiolog
virolog
host
immun
respons
common
highimpact
viral
respiratori
pathogen
icu
influenza
respiratori
synciti
viru
rsv
sar
varicellazost
viru
vzv
adenoviru
cytomegaloviru
cmv
viral
hemorrhag
fever
vhf
tabl
basic
foundat
clinic
care
public
health
medic
therapeut
virus
enhanc
laboratori
bedsid
individu
develop
primari
pneumonia
progress
ard
respiratori
symptom
persist
progress
minor
case
ard
develop
combin
pneumonia
ard
usual
occur
atrisk
individu
like
individu
chronic
lung
diseas
describ
healthi
individu
well
structur
influenza
viral
envelop
import
viral
infect
thu
host
cell
immun
envelop
contain
surfac
glycoprotein
essenti
viru
entri
host
cell
trimer
hemagglutinin
ha
structur
undergo
limit
proteolysi
host
cellular
proteas
furin
ha
bind
specif
sialosaccharid
found
surfac
respiratori
epitheli
cell
initi
cell
entri
neuraminidas
na
enzym
catalyz
remov
termin
sialic
acid
glycoprotein
help
degrad
respiratori
tract
mucu
releas
viral
progeni
cell
infect
thu
necessari
subsequ
viral
entri
viral
escap
host
cell
influenza
divid
subtyp
base
h
n
antigen
h
subtyp
found
multipl
avian
speci
anim
predomin
human
diseas
season
recent
avian
subtyp
increas
human
past
decad
infect
occur
virus
contain
aerosol
deposit
upper
respiratori
tract
epithelium
experiment
volunt
inocul
smallparticl
aerosol
close
mimic
natur
diseas
larg
drop
nose
illustr
easi
transmiss
cough
sneez
viru
attach
ha
penetr
columnar
epitheli
cell
predominantli
human
subtyp
bind
sialic
acid
found
ciliat
human
respiratori
tract
epithelium
hand
avian
influenza
subtyp
exampl
bind
preferenti
sialic
acid
found
gastrointestin
tract
water
fowl
epitheli
cell
human
conjunctiva
human
type
pneumocyt
preferenti
bind
specif
sialic
acid
receptor
illustr
differ
clinic
present
seen
avian
influenza
infect
human
conjunct
diarrhea
fulmin
alveolar
pneumonia
addit
underli
difficulti
humantohuman
transmiss
avian
strain
preferenti
bind
type
pneumocyt
requir
smaller
particl
aerosol
deep
inhal
alveoli
rather
larger
droplet
seen
season
influenza
transmiss
host
immun
occur
via
number
mechan
upon
receptor
bind
larg
cytokin
respons
occur
interleukin
il
interferon
gamma
predomin
tabl
clinic
immunolog
characterist
major
virus
found
intens
care
unit
howev
treatment
na
inhibitor
hour
may
provid
addit
benefit
fulli
studi
resist
low
within
commun
na
inhibitor
resist
alreadi
describ
clinic
isol
human
case
avian
influenza
sar
caus
novel
coronaviru
sarscov
first
detect
initi
outbreak
rapidli
spread
global
epidem
case
report
countri
fatal
rate
death
patient
older
death
children
sinc
initi
epidem
new
case
report
sar
appear
clinic
present
twostag
ill
initi
prodrom
character
fever
without
rigor
malais
headach
myalgia
occur
averag
day
contact
infect
individu
patient
also
mild
respiratori
symptom
nausea
diarrhea
respiratori
phase
appear
develop
approxim
day
onset
fever
fortyf
percent
patient
develop
hypoxemia
approxim
patient
progress
acut
lung
injuri
requir
mechan
ventil
sarscov
appear
origin
horsesho
bat
horsesho
bat
appear
natur
reservoir
viru
civet
cat
act
intermedi
host
allow
transmiss
human
like
rsv
influenza
sarscov
lipoprotein
envelop
unlik
rsv
influenza
viru
assembl
obtain
envelop
endoplasm
reticulum
sarscov
like
coronavirus
start
infect
upper
respiratori
tract
mucosa
sarscov
bind
lsign
two
function
receptor
respiratori
tract
epithelium
bind
local
inflamm
edema
increas
key
protect
role
acut
lung
injuri
reduc
alveolar
fluid
thu
bind
sarscov
may
contribut
dysregul
fluid
balanc
alveolar
space
addit
low
mannosebind
lectin
mbl
level
thought
play
role
sar
pathogenesi
mani
respiratori
infect
mbl
prevent
receptor
attach
activ
complement
enhanc
phagocytosi
sarscov
infect
low
defici
level
mbl
note
particularli
associ
mbl
haplotyp
bind
sarscov
along
lower
level
mbl
lead
higher
viral
level
increas
alveolar
edema
sever
acut
respiratori
failur
associ
sarscov
viral
spread
droplet
transmiss
although
mani
case
suggest
airborn
contact
rout
also
occur
spread
health
care
worker
wore
appropri
person
protect
equip
suggest
airborn
mode
addit
spread
aerosolgener
procedur
resuscit
cardiopulmonari
resuscit
medic
nebul
noninvas
ventil
support
mode
treatment
sar
larg
support
low
tidal
volum
mechan
ventil
numer
treatment
strategi
includ
corticosteroid
ribavirin
immunoglobulin
interferon
investig
sar
none
demonstr
provid
clinic
evid
benefit
vzv
infect
routin
occur
childhood
present
lowgrad
fever
malais
pharyng
vesicular
rash
primari
diseas
occur
throughout
year
usual
selflimit
immunocompet
host
vzv
pneumonia
rare
children
howev
frequent
complic
adult
account
major
hospit
vzv
varicella
pneumonia
develop
insidi
usual
day
onset
rash
progress
respiratori
failur
ard
risk
factor
vzv
pneumonia
ard
includ
pregnanc
smoke
immunosuppress
malign
corticosteroid
hiv
solidorgan
transplant
young
healthi
adult
rare
develop
ard
mortal
vzv
pneumonia
mortal
respiratori
failur
ensu
addit
complic
includ
enceph
hepat
secondari
skin
soft
tissu
infect
vzv
herp
viru
common
group
dna
virus
lipidcontain
envelop
surfac
glycoprotein
infect
start
upper
respiratori
tract
mucosa
surfac
glycoprotien
allow
fusion
lipid
envelop
respiratori
cell
membran
upon
cell
entri
viral
replic
assembl
occur
integr
viral
gene
cellular
dna
nake
capsid
acquir
envelop
nuclear
membran
releas
perinuclear
space
larg
vacuol
form
lead
clinic
vesicl
local
replic
spread
lead
seed
reticuloendotheli
system
ultim
viremia
lead
diffus
scatter
skin
lesion
associ
primari
varicella
viral
shed
last
onset
fever
lesion
crust
pneumonia
improv
humor
immun
cellmedi
immun
involv
protect
antibodi
direct
surfac
glycoprotein
lead
viral
neutral
cellular
immun
drive
local
inflamm
lead
cell
repair
vacuol
remov
viru
becom
latent
within
dorsal
root
ganglia
latenc
viral
dna
locat
cytoplasm
rather
integr
nuclear
dna
vzv
highli
contagi
transmiss
via
respiratori
droplet
direct
contact
lesion
envelop
sensit
deterg
air
dri
account
labil
vzv
fomit
adult
progress
pneumonia
ard
treatment
acyclovir
corticosteroid
shown
lessen
hospit
icu
stay
immunocompromis
person
previous
expos
vzv
varicellazost
immun
globulin
shown
use
prevent
diseas
symptomat
improv
adenoviru
one
common
caus
upper
respiratori
tract
infect
adult
children
clinic
diseas
usual
selflimit
upper
respiratori
tract
infect
associ
conjunct
howev
sever
lower
respiratori
diseas
occur
highrisk
healthi
individu
combin
pneumonia
ard
develop
minor
individu
usual
associ
conjunct
extrapulmonari
manifest
gastrointestin
diseas
hepat
mening
hemorrhag
cystiti
extrapulmonari
complic
along
ard
frequent
transplant
recipi
pneumonia
ard
appear
common
subtyp
e
type
subgroup
b
type
serogroup
also
document
mental
health
facil
recent
increas
respiratori
diseas
adult
note
past
year
serotyp
human
adenoviru
subtyp
exist
clinic
syndrom
vari
among
subtyp
howev
certain
subtyp
appear
increas
likelihood
lower
respiratori
tract
involv
appear
relat
viral
capsid
protein
unlik
influenza
rsv
sar
adenoviru
dna
viru
cover
protein
capsid
without
lipid
envelop
rodlik
structur
call
fiber
one
three
capsid
protein
type
hexon
penton
fiber
fiber
attach
apparatu
viral
adsorpt
cell
attach
occur
coxsackieadenoviru
receptor
receptor
coxsacki
b
viru
hexon
capsid
protein
appear
antigen
site
common
human
adenovirus
contain
site
show
type
specif
fiber
antigen
seem
primarili
typespecif
group
specif
wherea
penton
base
antigen
common
adenoviru
famili
upon
infect
respiratori
epitheli
cell
express
capsid
protein
surfac
lead
direct
cytotox
tcell
mhc
class
kill
cell
thu
epitheli
destruct
associ
submucos
edema
drive
clinic
find
lower
respiratori
diseas
addit
neutral
antibodi
direct
hexon
typespecif
antigen
provid
futur
protect
serotyp
adenoviru
rel
stabl
environment
surfac
long
period
time
thu
viral
spread
larg
associ
infect
fomit
spread
also
occur
via
droplet
transmiss
treatment
larg
support
sever
case
especi
immunosuppress
patient
antivir
therapi
attempt
clinic
studi
exist
sever
case
especi
immunocompromis
patient
ribavirin
cidofovir
antivir
therapi
attempt
control
clinic
trial
exist
cmv
common
viral
infect
caus
primari
latent
infect
seropreval
rate
rang
us
adult
popul
cmv
caus
wide
spectrum
ill
rang
asymptomat
infect
mononucleosi
syndrom
organspecif
complic
fulmin
multisystem
diseas
immunocompet
patient
like
present
minim
symptom
wherea
immunocompromis
patient
like
develop
organspecif
complic
fulmin
diseas
signific
sever
diseas
syndrom
found
lung
liver
kidney
heart
transplant
recipi
signific
morbid
mortal
usual
confin
immunocompromis
person
howev
previous
healthi
individu
present
organspecif
complic
even
present
fulmin
diseas
cmv
member
herp
viru
famili
like
member
famili
known
caus
latent
infect
like
herp
virus
cmv
envelop
viru
multipl
surfac
glycoprotein
glycoprotein
import
viral
entri
host
cell
target
host
cell
humor
cellmedi
immun
cellular
protein
serv
specif
receptor
cmv
entri
identifi
cmv
infect
cell
process
endocytosi
entri
occur
cmv
alter
host
immun
activ
multipl
gene
one
import
cmv
protein
prevent
cellular
molecul
reach
cell
surfac
prevent
recognit
destruct
lymphocyt
thu
cmv
genom
remain
infect
cell
avoid
immun
destruct
account
latenc
clinic
diseas
eventu
cellular
immun
respons
driven
high
level
anticmv
cell
lead
control
diseas
antibodi
cmv
provid
signific
immun
avoid
immun
detect
give
cmv
abil
remain
latent
infect
contribut
great
deal
seriou
cmv
diseas
evid
persist
cmv
genom
antigen
exist
mani
tissu
initi
infect
cmv
found
circul
mononuclear
cell
polymorphonuclear
neutrophil
viru
cultur
bodili
fluid
includ
blood
urin
stool
tear
semen
breast
milk
mucos
surfac
includ
throat
cervix
detect
cell
contain
cmv
intranuclear
inclus
renal
epitheli
tissu
pulmonari
secret
provid
evid
cmv
may
persist
tissu
well
cmv
antigen
also
detect
vascular
endotheli
cell
site
suggest
caus
vascular
inflamm
develop
atherosclerosi
immun
suppress
occur
patient
mean
hiv
infect
immunosuppress
therapi
antilymphocyt
antibodi
infus
cmv
reactiv
produc
endorgan
diseas
specif
pulmonari
standpoint
cmv
common
lung
transplant
caus
acut
pneumon
contribut
chronic
bronchiol
hiv
patient
cmv
pneumon
rare
postmortem
studi
suggest
pulmonari
diseas
cmv
occur
higher
rate
previous
recogn
cmv
transmit
via
mani
rout
transmiss
observ
among
famili
member
thought
secondari
close
contact
viral
shed
upper
respiratori
tract
among
children
employe
daycar
center
sexual
contact
blood
tissu
exposur
seroconvers
transfus
blood
product
organ
transplant
perinat
birth
breast
milk
sever
antivir
agent
avail
system
treatment
cmv
agent
includ
ganciclovir
valgancicilovir
foscarnet
cidofovir
vhf
includ
wide
number
geograph
distribut
virus
found
worldwid
includ
ebola
marburg
virus
rift
valley
fever
crimean
congo
hemorrhag
fever
lassa
fever
yellow
fever
dengu
fever
ebola
marburg
virus
famili
filovirida
although
underli
pathophysiolog
differ
slightli
vhf
marburg
ebola
virus
serv
classic
templat
marburg
viru
singl
speci
wherea
ebola
four
differ
speci
vari
virul
human
clinic
manifest
marburg
ebola
virus
similar
present
higher
mortal
ebola
zair
marburg
viru
major
differ
initi
incub
period
exposur
viru
day
clinic
diseas
begin
onset
fever
chill
malais
sever
headach
nausea
vomit
diarrhea
abdomin
pain
initi
infect
macrophag
dendrit
cell
initi
site
viral
replic
follow
spread
reticuloendotheli
system
herald
initi
onset
symptom
macrophag
infect
tissu
undergo
necrosi
overwhelm
cytokin
respons
occur
lead
abrupt
prostrat
stupor
hypotens
particularli
tumor
necrosi
factor
tnf
macrophag
chemotact
protein
nitric
oxid
level
markedli
increas
vhfinfect
macrophag
along
noninfect
macrophag
stimul
cytokin
releas
cell
surfac
tissu
factor
subsequ
trigger
extrins
coagul
pathway
clinic
laboratori
find
impair
coagul
increas
conjunctiv
soft
tissu
bleed
shortli
follow
case
massiv
hemorrhag
occur
gastrointestin
urinari
tract
rare
instanc
alveolar
hemorrhag
occur
onset
maculopapular
rash
arm
trunk
also
appear
classic
may
distinct
sign
along
bleed
hypotens
multiorgan
failur
occur
eventu
lead
death
overwhelm
viremia
result
macrophag
dendrit
cell
apoptosi
lead
impair
humor
immun
turn
lead
increas
viral
product
ultim
result
rapid
overwhelm
shock
seen
vhf
transmiss
appear
occur
contact
nonhuman
primat
infect
individu
specif
therapi
avail
patient
manag
includ
support
care
case
zair
outbreak
ebola
whole
blood
igg
antibodi
ebola
may
improv
outcom
although
subsequ
analysi
suggest
patient
like
surviv
even
without
treatment
hantaviru
one
four
major
genera
within
famili
bunyavirida
famili
anim
virus
spread
via
arthropodvertebr
cycl
hantaviru
caus
two
sever
acut
febril
ill
hemorrhag
fever
renal
syndrom
hfr
found
old
world
hantaviru
cardiopulmonari
syndrom
hp
found
new
world
hp
first
classifi
southwestern
us
new
speci
term
sin
nombr
viru
identifi
outbreak
four
corner
region
southwestern
us
north
america
diseas
larg
report
southwest
california
case
report
canada
europ
china
chile
argentina
part
south
america
outbreak
often
cyclic
focal
affect
weather
climat
variabl
effect
rodent
popul
symptom
begin
prodrom
fever
chill
myalgia
hfr
hp
also
accompani
abdomin
pain
gastrointestin
disturb
hp
initi
absenc
upper
respiratori
symptom
day
modest
dri
cough
dyspnea
develop
due
sever
increas
vascular
permeabl
associ
hp
diseas
progress
rapidli
within
hour
respiratori
failur
shock
ard
coagulopathi
arrhythmia
resolut
also
occur
rapidli
hypoxia
manag
shock
fatal
vascular
leak
revers
day
recoveri
appar
complet
notabl
thrombocytopenia
immunoblastpredomin
leukocytosi
characterist
earli
cardiopulmonari
phase
exact
mechan
ard
shock
coagulopathi
unclear
suspect
immun
respons
rather
viru
caus
capillari
leak
shock
intens
cellular
immun
respons
alter
endotheli
cell
barrier
function
harm
hantaviru
caus
increas
releas
tnf
alpha
interferon
increas
mhc
antigen
present
also
intens
tcell
respons
sicker
patient
appear
result
massiv
acut
capillari
leak
syndrom
shockinduc
mechan
thought
due
releas
kinin
cytokin
syndrom
clinic
present
rapid
resolut
histopatholog
find
interstiti
infiltr
lymphocyt
alveolar
pulmonari
edema
without
mark
necrosi
support
underli
process
treatment
mainli
support
extracorpor
membran
oxygen
use
case
ribavirin
effect
hfr
hp
mortal
remain
roughli
viral
infect
icu
common
outpati
set
becom
less
common
icu
howev
small
number
viral
infect
lower
respiratori
tract
diseas
subsequ
respiratori
failur
viral
pathogen
vari
greatli
clinic
diseas
rapid
fulmin
respiratori
failur
shock
vhf
chronic
latent
diseas
immunosuppress
cmv
howev
virus
commonli
lipid
envelop
except
adenoviru
surfac
protein
glycoprotien
allow
attach
cell
entri
virul
host
respons
infect
vari
primarili
cellular
articl
part
review
seri
infect
edit
steven
opal
articl
seri
found
onlin
http
ccforumcomarticl
themeseriesasp
seriesccinfect
humor
caus
respiratori
diseas
great
public
health
concern
particularli
novel
strain
influenza
adenoviru
sar
vhf
understand
basic
viral
pathogenesi
along
host
respons
allow
foundat
treatment
public
health
respons
within
icu
